Related Experiment Video
Updated: Apr 21, 2026
06:24
Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies
Published on: January 10, 2025
1.8K
What are the concerns about custom-compounded "bioidentical" hormone therapy?
1From the University of Virginia Midlife Health Center, Charlottesville, VA.
Menopause (New York, N.Y.)
|November 12, 2014
Summary
Custom-compounded bioidentical hormones lack safety and efficacy data. FDA-approved hormone therapy offers a regulated and tested alternative, avoiding risks associated with custom preparations.
Area of Science:
- Endocrinology
- Pharmacology
- Regulatory Science
Background:
- Custom-compounded bioidentical hormone products often lack rigorous scientific validation.
- Concerns exist regarding the safety, efficacy, and quality control of these unregulated preparations.
Discussion:
- Unsubstantiated claims frequently surround custom-compounded hormones.
- The absence of comprehensive data raises significant safety and efficacy questions.
- Comparison with FDA-approved therapies highlights disparities in regulation and testing.
Key Insights:
- Custom-compounded bioidentical hormones are not supported by robust scientific evidence.
- FDA-approved hormone therapies undergo stringent testing and regulatory oversight.
- Patients face potential risks due to the lack of quality control in compounded products.
Outlook:
- Further research is needed to establish the safety and efficacy of compounded hormones.
- Regulatory bodies emphasize the importance of using FDA-approved treatments.
- Informed patient choices require clear understanding of the risks versus benefits.
Related Concept Videos
01:18Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules
406
Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...
406
01:28Drug Products: Biologics, Biosimilars and Interchangeables
367
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
367
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
227
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
227
01:24Dosage Regimen: Individualization
378
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
378
01:16Bioequivalence: Overview
2.3K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
2.3K
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
251
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
251